SUBSCRIBE

Insulin glargine biosimilar Semglee launched in US

 Posted 18/09/2020

The partnership of US-based drugmaker Mylan and Indian biologicals specialist Biocon announced on 31 August 2020 the launch of their insulin glargine pr...

more
Biosimilars allow fast access to biological dru... Biosimilars/Research | Posted 18/09/2020
Brazil publishes pathway for accelerating innov... Policies & Legislation | Posted 18/09/2020
Ligand to acquire biosimilars manufacturer Pfenex Pharma News | Posted 18/09/2020
What oncologists do not understand about biosim... Biosimilars/Research | Posted 18/09/2020
The benefits of tracking generic drug quality Generics/General | Posted 18/09/2020
Country scorecards show biosimilar sustainability Biosimilars/General | Posted 18/09/2020
Inter partes review and the generic drug industry Policies & Legislation | Posted 18/09/2020
DIA Biosimilars Conference 2020 Conferences | Posted 18/09/2020
Budget savings from biosimilar infliximab in th... Biosimilars/Research | Posted 11/09/2020
Turkey 2016 COVER V16E31DG
Samsung Bioepis launches Ontruzant in Brazil Biosimilars/News | Posted 11/09/2020
Duopharma to establish Malaysia’s first commerc... Biosimilars/General | Posted 11/09/2020
Cadila Pharmaceuticals launches two similar bio... Biosimilars/News | Posted 11/09/2020
Celltrion’s biosimilars effective against gastr... Biosimilars/Research | Posted 11/09/2020
Mylan launches first generic of Tecfidera in th... Generics/News | Posted 11/09/2020
Evaluating reasons for US low generics substitu... Generics/Research | Posted 11/09/2020
Kodak Pharmaceutical deal under scrutiny Pharma News | Posted 11/09/2020
EC approval for trastuzumab biosimilar Zercepac Biosimilars/News | Posted 04/09/2020
Center for Biologics Evaluation and Research to... Guidelines | Posted 04/09/2020
WHO prequalifies Celltrion’s trastuzumab biosim... Biosimilars/General | Posted 04/09/2020
Bio-Thera partners with Pharmapark to market go... Pharma News | Posted 04/09/2020
Solutions to US low biosimilars uptake Policies & Legislation | Posted 04/09/2020
Biosimilar infliximab could save Canada over CA... Reports | Posted 04/09/2020
ST002293
Monoclonal antibody biosimilars and cancer in t... Biosimilars/Research | Posted 04/09/2020
Lupin’s generic diabetes drug approved and asth... Generics/News | Posted 04/09/2020
The biosimilars market in Latin America: a summary Biosimilars/Research | Posted 28/08/2020
EMA recommends approval of bevacizumab biosimil... Biosimilars/News | Posted 28/08/2020
Cost savings from biosimilars in Canada: actual... Reports | Posted 28/08/2020
AA010964
Teva changes course in Japan and the US Pharma News | Posted 28/08/2020
Alexion delays Soliris biosimilar until 2025 Policies & Legislation | Posted 28/08/2020
Generics substitution in Finland: a pharmacy di... Generics/Research | Posted 28/08/2020
Clinical trials for trastuzumab biosimilars Biosimilars/General | Posted 28/08/2020
Two additions to the South Korean generics market Generics/News | Posted 28/08/2020
EU MedSoc 2016 Cover V15L30DG
Sustainable biosimilar policies in Europe Biosimilars/Research | Posted 31/07/2020
US policy brief identifies barriers to biosimil... Policies & Legislation | Posted 31/07/2020
EC approval for Sanofi’s insulin aspart biosimilar Biosimilars/News | Posted 31/07/2020
Genentech and Amgen settle biosimilar disputes Policies & Legislation | Posted 31/07/2020
Biosimilar infliximab uptake in Canada Reports | Posted 31/07/2020
Study reveals link between socioeconomic status... Generics/Research | Posted 31/07/2020
Biosimilar infliximab reduces medication costs... Biosimilars/Research | Posted 31/07/2020
Generics reform in Korea Guidelines | Posted 31/07/2020
Trastuzumab biosimilar Kanjinti is stable over... Biosimilars/Research | Posted 24/07/2020
Low levels of biosimilar uptake in Canada Reports | Posted 24/07/2020
EMA approves bevacizumab and teriparatide biosi... Biosimilars/News | Posted 24/07/2020
China publishes new patent law amendment Policies & Legislation | Posted 24/07/2020
FDA approves pegfilgrastim biosimilar Nyvepria Biosimilars/News | Posted 24/07/2020
ST002293
Biosimilar pipelines for Korean firms looking h... Biosimilars/General | Posted 24/07/2020
Perrigo sells its UK generic drug business Pharma News | Posted 24/07/2020
Indian generics makers begin to dispatch remdes... Generics/News | Posted 24/07/2020
US biosimilars pipeline for immunosuppressants,... Reports | Posted 17/07/2020
more

NON-BIOLOGICAL COMPLEX DRUGS

FDA issues final guidance on liposome drug products Posted 27/04/2018

On 4 April 2018, the US Food and Drug Administration (FDA) issued a new draft...

more


FDA approves 40 mg follow-on version of glatira... Non‐Biological Complex Drugs/News | Posted 09/03/2018
Mylan launches first follow-on glatiramer aceta... Non‐Biological Complex Drugs/News | Posted 15/02/2018
Biosimilars and follow-on NBCDs for MS in Europ... Non‐Biological Complex Drugs/Research | Posted 19/01/2018
Impax announces FDA approval of follow-on sevel... Non‐Biological Complex Drugs/News | Posted 17/11/2017
FDA approves follow-on version of sevelamer Non‐Biological Complex Drugs/News | Posted 30/06/2017
Challenges in the regulation of NBCDs Non‐Biological Complex Drugs/Research | Posted 12/05/2017
Scientific and regulatory considerations for fo... Non‐Biological Complex Drugs/Research | Posted 05/05/2017
Equivalence of complex drug products Non‐Biological Complex Drugs/Reports | Posted 14/04/2017
Follow-up studies needed to ensure safety for f... Non‐Biological Complex Drugs/Research | Posted 31/03/2017
Warning letter causes delays for follow-on glat... Non‐Biological Complex Drugs/News | Posted 17/03/2017
Is the EU ready for non-biological complex drug... Non‐Biological Complex Drugs/Research | Posted 03/03/2017
Follow-on versions of glatiramer acetate in Rus... Non‐Biological Complex Drugs/News | Posted 24/02/2017
Non-biological complex drugs and pharmacopoeias Non‐Biological Complex Drugs/Research | Posted 10/02/2017
In vitro analysis of follow-on versions of seve... Non‐Biological Complex Drugs/Research | Posted 18/11/2016
Determining the bioequivalence of follow-on iro... Non‐Biological Complex Drugs/Reports | Posted 04/11/2016
FDA to set up abbreviated pathway for complex p... Non‐Biological Complex Drugs/Polices & Legislation | Posted 21/10/2016
Challenges in the assessment of ophthalmic emul... Non‐Biological Complex Drugs/Reports | Posted 07/10/2016
Cancer lab to evaluate bioequivalence of nanosi... Non‐Biological Complex Drugs/News | Posted 23/09/2016
A conference on ‘Equivalence of Complex Drug Pr... Non‐Biological Complex Drugs/News | Posted 09/09/2016
Collaboration to introduce nanotechnologies in... Non‐Biological Complex Drugs/News | Posted 26/08/2016
Iron carbohydrate follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 12/08/2016
Rigorous approach used to approve a follow-on v... Non‐Biological Complex Drugs/Research | Posted 29/07/2016
US guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 10/06/2016
Non-biological complex drugs and their follow-o... Non‐Biological Complex Drugs/Research | Posted 03/06/2016
Is a new pathway for NBCDs on the way in the US? Non‐Biological Complex Drugs/Polices & Legislation | Posted 27/05/2016
Follow-on glatiramer acetate gains European app... Non‐Biological Complex Drugs/News | Posted 13/05/2016
FDA includes follow-on versions in its new cycl... Non‐Biological Complex Drugs/Guidelines | Posted 29/04/2016
Switching between originator and follow-on iron... Non‐Biological Complex Drugs/Research | Posted 22/04/2016
Follow-on intravenous iron formulations in haem... Non‐Biological Complex Drugs/Research | Posted 01/04/2016
Glatiramoid follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/03/2016
FDA includes follow-on versions in its new lipo... Non‐Biological Complex Drugs/Guidelines | Posted 26/02/2016
EU guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 22/01/2016
GDUFA regulatory priorities for 2016 include co... Non‐Biological Complex Drugs/Polices & Legislation | Posted 11/12/2015
Liposomal follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/12/2015
Regulations for follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 13/11/2015
Status and regulatory issues surrounding follow... Non‐Biological Complex Drugs/Reports | Posted 05/11/2015
Follow-on glatiramer acetate (M356) claimed as... Non‐Biological Complex Drugs/Research | Posted 05/11/2015
EMA issues reflection paper for follow-on versi... Non‐Biological Complex Drugs/Guidelines | Posted 05/11/2015
FDA approves first follow-on version of glatira... Non‐Biological Complex Drugs/News | Posted 05/11/2015
more

Country Focus

All countries

Sign up today to receive weekly news on the latest developments in generic and biosimilar medicines!

Generics News Research General

more

Biosimilars News Research General

more

More editorial sections